Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds

BACKGROUND: The mRNA-based COVID-19 vaccine was introduced to the general public in December 2020. Shortly thereafter, safety concerns were raised due to the reporting of allergic reactions. Allergy-related disorders were suspected to be significant risk factors and the excipient polyethylene glycol...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribak, Yaarit, Rubin, Limor, Talmon, Aviv, Dranitzki, Zvi, Shamriz, Oded, Hershkowitz, Isca, Tal, Yuval, Hershko, Alon Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465362/
https://www.ncbi.nlm.nih.gov/pubmed/37654487
http://dx.doi.org/10.3389/fimmu.2023.1172896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465362/
https://www.ncbi.nlm.nih.gov/pubmed/37654487
http://dx.doi.org/10.3389/fimmu.2023.1172896

Ejemplares similares